AUSTIN, Texas, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that its lead drug candidate PTI-125 has been assigned the chemical drug name sumifilam by the United States Adopted Names (USAN) Council. Future references to PTI-125 will be sumifilam. A commercial brand name for sumifilam is expected to be announced at a future date. Sumifilam is an investigational new drug and has not been approved for any indication.
Sumifilam is the first of a new class of drugs that bind filamin proteins. For this reason, USAN is expected to grant this class of drugs its own name stem, i.e., -filam. Any future drug by any company that targets filamin protein is expected to incorporate the -filam name stem as part of its drug name.
"A very famous author once asked, what's in a name?" said Remi Barbier, President & CEO. "With apologies to that author, that which we call sumifilam by any other name would still elicit palpable excitement for an absolutely new type of drug therapy for Alzheimer's disease."